

OCT 1 1 2005

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Harold C. Wegner Foley & Lardner Washington Harbour, Suite 500 3000 K Street NW Washington DC 20007-5109 In Re: Patent Term Extension Application for U.S. Patent No. 5,362,755

A determination has been made that U.S. Patent No. 5,362,755, which claims the drug product XOPONEX (levalbuterol HCl), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 503 days.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Director will issue a certificate of extension, under seal, for a period of 503 days.

The period of extension has been calculated using the Food and Drug Administration (FDA) determination of the length of the regulatory review period published in the Federal Register of July 12, 2004 (69 Fed. Reg. 41812). Under 35 U.S.C. § 156(c):

Period of Extension = 
$$\frac{1}{2}$$
 (Testing Phase) + Approval Phase =  $\frac{1}{2}$  (824 - 0) + 634 = 1,046 days

Since the regulatory review period began March 30, 1995, after the patent issue date (November 8, 1994), the entire period has been considered in the above determination. No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

However, the 14 year exception of 35 U.S.C. § 156(c)(3) operates to limit the term of the extension in the present situation because it provides that the period remaining in the term of the patent measured from the date of approval of the approved product plus any patent term extension cannot exceed fourteen years. The period of extension calculated above, 1,046 days, would extend the patent from November 8, 1994 (35 U.S.C. § 154) to September 19, 2014, which is beyond the 14-year limit (the approval date is March 25, 1999, thus the 14 year limit is March 25, 2013). The period of extension is thus limited to March 25, 2013, by operation of 35 U.S.C. § 156(c)(3). Accordingly, the period of extension is the number of days to extend the term of the patent from its original expiration date, November 8, 2011, to and including March 25, 2013, or 503 days.

The limitations of 35 U.S.C. § 156 (g)(6) do not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:

5,362,755

Granted:

November 8, 1994

Applicant:

Timothy J. Barberich, et al.

Page 2

Owner of Record:

Sepacor, Inc.

Title:

Method for Treating Asthma Using Optically Pure

(R)-Albuterol

Classification:

514/649

Product Trade Name:

XOPONEX (levalbuterol HCl)

Term Extended:

503 days

Expiration of Extension:

March 25, 2013

Any correspondence with respect to this matter should be addressed as follows:

By mail:

Mail Stop Patent Ext. Commissioner for Patents

By FAX:

(571) 273-7744

P.O. Box 1450

Alexandria, VA 22313-1450.

Telephone inquiries related to this determination should be directed to the undersigned at (571) 272-7744

Karin L. Ferriter

Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner for Patent Examination Policy

cc:

Office of Regulatory Policy

HFD - 13

5600 Fishers Lane Rockville, MD 20857

Attention: Claudia Grillo

RE: XOPONEX (levalbuterol HCl)

FDA Docket No.: 99E-5116